A PIONEERING Alloa-based health technology company has acquired a US distributor as it drives forward ambitions for rapid global growth.

Emblation, which has developed a non-ablative treatment for common and plantar warts, has acquired Saorsa Inc to help fuel the next phase of its ambitious development.

As part of the seven-figure deal, Saorsa will become Emblation Inc to spearhead growth in the US, having already built up an impressive record as the sole distributor of its pioneering Swift® Microwave Therapy technology in the country.

Gary Beale, co-founder and CEO of Emblation, said: “This is a huge step towards us achieving both our commercial and clinical goals over the next four years.

“The US is the largest global healthcare market and from an Emblation perspective, represents a major area for growth.

“The scale and potential impact of this one acquisition is massive for us.

“It is an exciting time for everyone in the firm and I’m delighted we will now be integrating such an enthusiastic and energetic team to the Emblation global family.”

The award-winning medical technology company has been on a mission to revolutionise the way microwave energy is used in healthcare.

Its aim is to improve on traditional treatments, using the unique advantages microwaves deliver with accurate, repeatable procedures and better clinical outcomes.

Their Swift provides podiatrists and dermatologists with a new, precise, and easy procedure for soft tissue lesions.

The treatment works by delivering a highly controlled dose of energy into the tissue, creating heat which stimulates an immune response.

This delivers highly effective outcomes for stubborn skin lesions, such as warts and verrucae.

Emblation’s technology is transforming the treatment of HPV infections globally and is widely used in dermatology, podiatry and oncology, with a number of disruptive applications under development in the fields of cardiology and gynaecology.

Speaking of the US acquisition, Mr Beale added: “When we began discussing our plans for the US market, they were determined to take advantage of the opportunity and as a result, they founded Saorsa alongside two investors and former colleagues in 2018.

“Since then, Saorsa has been the exclusive supplier of Swift in the US, rolling out more than 400 devices, with more than 1,000 practitioners trained in its use and more than 50,000 treatments carried out on skin lesions.”

The firm was founded by Gary Beale and Eamon McErlean, who met during post-graduate studies at the University in Edinburgh.

The pair went on to launch Swift in 2016.